Cite
Matsuda M, Tamura R, Kanno K, et al. Impact of dyslipidemic components of metabolic syndrome, adiponectin levels, and anti-diabetes medications on malondialdehyde-modified low-density lipoprotein levels in statin-treated diabetes patients with coronary artery disease. Diabetol Metab Syndr. 2013;5(1):77doi: 10.1186/1758-5996-5-77.
Matsuda, M., Tamura, R., Kanno, K., Segawa, T., Kinoshita, H., Nishimoto, O., Nishiyama, H., & Kawamoto, T. (2013). Impact of dyslipidemic components of metabolic syndrome, adiponectin levels, and anti-diabetes medications on malondialdehyde-modified low-density lipoprotein levels in statin-treated diabetes patients with coronary artery disease. Diabetology & metabolic syndrome, 5(1), 77. https://doi.org/10.1186/1758-5996-5-77
Matsuda, Morihiro, et al. "Impact of dyslipidemic components of metabolic syndrome, adiponectin levels, and anti-diabetes medications on malondialdehyde-modified low-density lipoprotein levels in statin-treated diabetes patients with coronary artery disease." Diabetology & metabolic syndrome vol. 5,1 (2013): 77. doi: https://doi.org/10.1186/1758-5996-5-77
Matsuda M, Tamura R, Kanno K, Segawa T, Kinoshita H, Nishimoto O, Nishiyama H, Kawamoto T. Impact of dyslipidemic components of metabolic syndrome, adiponectin levels, and anti-diabetes medications on malondialdehyde-modified low-density lipoprotein levels in statin-treated diabetes patients with coronary artery disease. Diabetol Metab Syndr. 2013 Dec 06;5(1):77. doi: 10.1186/1758-5996-5-77. PMID: 24314067; PMCID: PMC4029151.
Copy
Download .nbib